Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 445
- Registration Number
- NCT00819052
- Locations
- 🇺🇸
1100.1526.1012 Boehringer Ingelheim Investigational Site, Beverly Hills, California, United States
🇫🇷1100.1526.3306A Boehringer Ingelheim Investigational Site, Bobigny, France
🇫🇷1100.1526.3304A Boehringer Ingelheim Investigational Site, Nice cedex 3, France
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
- Conditions
- Asthma
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 226
- Registration Number
- NCT00818454
- Locations
- 🇺🇸
1012.57.114 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸1012.57.143 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸1012.57.134 Boehringer Ingelheim Investigational Site, Centennial, Colorado, United States
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT00809133
- Locations
- 🇬🇧
1200.12.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1200.12.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5897
- Registration Number
- NCT00808067
- Locations
- 🇺🇸
1160.71.0119 Boehringer Ingelheim Investigational Site, Tupelo, Mississippi, United States
🇺🇸1160.71.0038 Boehringer Ingelheim Investigational Site, Hot Springs, Arkansas, United States
🇺🇸1160.71.0482 Boehringer Ingelheim Investigational Site, Guilford, Connecticut, United States
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 718
- Registration Number
- NCT00806819
- Locations
- 🇺🇦
Boehringer Ingelheim Investigational Site, Vinnytsia, Ukraine
Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort
- Conditions
- HIV Infections
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00805857
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1314
- Registration Number
- NCT00805194
- Locations
- 🇧🇾
Brest Regional Clinical, Brest Region, Belarus
🇦🇹KH St. Vinzenz, Zams, Int. Abtlg., Kufstein, Austria
🇧🇬Specialized Hospital for Active Treatment in Oncolcogy, Sofia, Bulgaria
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT00804856
- Locations
- 🇫🇷
HOP Edouard Herriot, Lyon Cedex 03, France
🇨🇦Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada
🇫🇷HOP Clémenceau, Hémato, Caen, Caen, France
First Presentation of Parkinson Disease Patients to Neurologist
- Conditions
- Parkinson Disease
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2448
- Registration Number
- NCT00802178
- Locations
- 🇸🇮
Boehringer ingelheim Investigational Site 2, Maribor, Slovenia
🇸🇮Boehringer ingelheim Investigational Site 3, Maribor, Slovenia
🇷🇴Boehringer Ingelheim Investigational Site 8, Bucuresti, Romania
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 46
- Registration Number
- NCT00801294
- Locations
- 🇫🇷
1239.2.3301D Hôpital Saint Antoine, Paris Cedex 12, France
🇫🇷1239.2.3301G Hôpital Saint Antoine, Paris Cedex 12, France
🇫🇷1239.2.3301H Hôpital Saint Antoine, Paris Cedex 12, France